title: [Rituximab therapy for relapsing IgG4-autoimmune pancreatitis and cholangitis - a case report].
abstract: We report a patient with autoimmune pancreatitis and cholangitis. During a period of 3 years and despite therapy with steroids and immunmodulatory drugs such as azathioprine and mycophenolate mofetil he suffered from multiple relapse episodes including bile duct stenoses requiring endoscopic interventions. After initiation of therapy with the monoclonal CD20 antibody Rituximab, steroids could be stopped completely and the patient remains in remission. Rituximab should be considered in therapy of relapsing autoimmune pancreatitis and cholangitis.
authors.affiliation: Innere Medizin, Klinikum Ludwigsburg.
authors.forename: J
authors.initials: J
authors.lastname: Mueller
authors.affiliation: Innere Medizin, Klinikum Ludwigsburg.
authors.forename: A
authors.initials: A
authors.lastname: Schmidt
authors.affiliation: Pathologie, Klinikum Ludwigsburg.
authors.forename: G
authors.initials: G
authors.lastname: Herrmann
authors.affiliation: Innere Medizin, Klinikum Ludwigsburg.
authors.forename: K
authors.initials: K
authors.lastname: Caca
mesh_terms: D000328:Adult; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D002761:Cholangitis / Q000188:drug therapy* / Q000276:immunology; D002908:Chronic Disease; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007155:Immunologic Factors / Q000008:administration & dosage; D008297:Male; D010195:Pancreatitis / Q000188:drug therapy* / Q000276:immunology*; D000069283:Rituximab / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D007074:Immunoglobulin G; D007155:Immunologic Factors; D000069283:Rituximab